Publications
Detailed Information
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Soo Yeon | - |
dc.contributor.author | Noh, Woo Chul | - |
dc.contributor.author | Ahn, Sei-Hyun | - |
dc.contributor.author | Kim, Hyun-Ah | - |
dc.contributor.author | Ryu, Jai Min | - |
dc.contributor.author | Kim, Seung Il | - |
dc.contributor.author | Lee, Eun-Gyeong | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Jung, Yongsik | - |
dc.contributor.author | Park, Min Ho | - |
dc.contributor.author | Park, Kyong Hwa | - |
dc.contributor.author | Kang, Su Hwan | - |
dc.contributor.author | Jeong, Joon | - |
dc.contributor.author | Park, Eunhwa | - |
dc.contributor.author | Kim, Sung Yong | - |
dc.contributor.author | Lee, Min Hyuk | - |
dc.contributor.author | Kim, Lee Su | - |
dc.contributor.author | Lim, Woosung | - |
dc.contributor.author | Kim, Seonok | - |
dc.contributor.author | Kim, Hee Jeong | - |
dc.date.accessioned | 2023-11-30T05:48:14Z | - |
dc.date.available | 2023-11-30T05:48:14Z | - |
dc.date.created | 2023-11-15 | - |
dc.date.created | 2023-11-15 | - |
dc.date.issued | 2023-11 | - |
dc.identifier.citation | Journal of Clinical Oncology, Vol.41 No.31, pp.4864-4871 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://hdl.handle.net/10371/197567 | - |
dc.description.abstract | PURPOSETo determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial.PATIENTS AND METHODSThis study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS).RESULTSAt 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25).CONCLUSIONAdding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy. | - |
dc.language | 영어 | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.title | Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1200/JCO.23.00557 | - |
dc.citation.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.wosid | 001096174500007 | - |
dc.identifier.scopusid | 2-s2.0-85175357595 | - |
dc.citation.endpage | 4871 | - |
dc.citation.number | 31 | - |
dc.citation.startpage | 4864 | - |
dc.citation.volume | 41 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.